Shanghai Moyom Biotechnology unveiled its breakthrough regenerative aesthetic innovation, Aphranel MagiCCrystal CaHA Filler, during an international product debut in Shanghai on May 8, 2025. The event, themed "APHRANEL: Code Breaker, World Maker," brought together senior policy makers, medical experts, and industry leaders, highlighting China's emerging role in developing next-generation regenerative materials for aesthetic applications.
First Chinese CaHA Filler Achieves Global Regulatory Milestone
Aphranel MagiCCrystal represents a significant achievement as the first injectable calcium hydroxylapatite (CaHA) microsphere-based dermal filler developed in China to receive NMPA Class III medical device certification. The product has simultaneously secured EU Medical Device certification, MDSAP compliance, and regulatory clearance from Mexico's COFEPRIS, enabling market access across Asia, Europe, and Latin America.
The filler's formulation leverages proprietary manufacturing processes that precisely control particle size (30-35μm), porosity, and degradation rates. Its distinctive ACD-MT™ "raspberry-like" through-hole microsphere morphology increases porosity by 40% compared to competing products, while the PCD-ETT™ physically crosslinked gel matrix contributes to its structural integrity and tissue integration.
Technical specifications reveal impressive performance metrics, with a viscoelastic modulus (G' value) reaching 5500Pa, enabling long-lasting three-dimensional supporting effects. The pre-mixing technology combining CaHA and carboxymethyl cellulose (CMC) ensures uniform particle suspension and smoother injection delivery.
Clinical Validation and Expert Endorsement
The scientific program at the launch featured keynote lectures from internationally recognized experts in plastic and aesthetic surgery, including Prof. Qi Zuoliang, Prof. Cui Haiyan, Prof. Luo Shengkang, Prof. Chen Guangyu, Prof. Li Ya, and Dr. Stefan Lipp from Germany.
Lin Guangming, Chairman of Moyom Biotechnology, emphasized the company's decade-long R&D journey during the product launch, highlighting its commitment to "restoring the medical essence of aesthetic treatments." This scientific rigor has enabled China's transition from industry follower to global innovator.
"Aphranel demonstrates how 'Created in China' can achieve global excellence through medical innovation," said Chairman Lin. "The innovation establishes new benchmarks for aesthetic safety and natural results worldwide."
The product's safety profile has been validated through 31 biochemical tests, demonstrating an inflammation rate 30% lower than the current state of the art, while maintaining full biodegradability. These characteristics align with global standards in regenerative injectables and address growing demands for safer aesthetic treatments.
Strategic Research Collaborations and Clinical Partnerships
Shanghai Moyom Biotechnology has built an extensive innovation network through a "Chinese R&D + Local transformation" model. The company has established research collaborations with prestigious institutions including Nanjing Tech University and the Chinese Academy of Sciences to advance biomaterial technology.
Clinical validation has been conducted in partnership with authoritative institutions such as the Plastic Surgery Hospital of the Chinese Academy of Medical Sciences and Shanghai Ninth People's Hospital. During the launch event, Moyom announced 68 newly established clinical collaborations with global medical aesthetics centers, forming the basis for long-term multicenter studies and physician education initiatives.
The company has also engaged in international expansion by establishing joint laboratories with medical aesthetics experts from Germany and Brazil to promote localized adaptation of its technology. This global approach reflects the company's commitment to meeting diverse market needs while maintaining consistent quality standards.
Capital Investment Fueling Innovation
In 2024, Moyom Biotechnology completed nearly 100 million RMB of Plan B+ financing, led by Boyuan Capital and SAIC Hengxu Capital, with cumulative financing exceeding 500 million RMB. These funds will support globalization capacity expansion and second-generation absorbable implant research and development.
The company's core team brings together PhDs from top universities such as Fudan University and Shanghai Jiao Tong University, as well as technical experts from listed healthcare companies. This multidisciplinary expertise has been crucial in developing the innovative properties of the Aphranel MagiCCrystal CaHA Filler.
Market Implications and Industry Impact
Calcium hydroxylapatite (CaHA) microspheres have become a core material in the global bio-stimulating injection field due to their excellent biocompatibility and biodegradability, with a market adoption rate 71% higher than poly-L-lactic acid (PLLA). Aphranel's entry into this market segment represents a significant advancement in treatment options.
The approval of Aphranel MagiCCrystal CaHA Filler marks an important milestone in the industry's compliance standards and demonstrates China's growing capability to develop innovative medical aesthetic products that meet global regulatory requirements.
As the medical aesthetics market continues to expand globally, products like Aphranel that combine safety, efficacy, and technological innovation are positioned to capture significant market share while elevating treatment standards. The product's global regulatory approvals signal a new era where Chinese medical innovations can achieve international recognition and adoption.
